FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Karen Vanhoorelbeke

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Phenomena

Protein Binding

Disorders

Concepts & Ideas

Protein Structure, Tertiary

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Karen De Ceunynck; Simon F De Meyer; Karen Vanhoorelbeke
Unwinding the von Willebrand factor strings puzzle.
Hendrik Feys; Sam Hou; Seb Lamprecht; Harald Mottl; Inge Pareyn; Jan Roodt; Walter J Van Rensburg; Nele Vandeputte; Hans Deckmyn; Karen Vanhoorelbeke
Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.
Katleen Broos; Simon F De Meyer; Hendrik B Feys; Karen Vanhoorelbeke; Hans Deckmyn
Blood platelet biochemistry.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Karen Vanhoorelbeke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Karen De Ceunynck; Simon F De Meyer; Karen Vanhoorelbeke
Unwinding the von Willebrand factor strings puzzle.
Blood 2013;121(2):270-7.
2012: Hendrik Feys; Sam Hou; Seb Lamprecht; Harald Mottl; Inge Pareyn; Jan Roodt; Walter J Van Rensburg; Nele Vandeputte; Hans Deckmyn; Karen Vanhoorelbeke
Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.
Blood 2012;120(17):3611-4.
2012: Katleen Broos; Simon F De Meyer; Hendrik B Feys; Karen Vanhoorelbeke; Hans Deckmyn
Blood platelet biochemistry.
Thrombosis research 2012;129(3):245-9.
2012: Hans Deckmyn; Katleen Broos; Simon F De Meyer; Karen Vanhoorelbeke
Inhibitors of the interactions between collagen and its receptors on platelets.
Handbook of experimental pharmacology 2012;(210):311-37.
2011: S F DE Meyer; Hans Deckmyn; U Budde; Karen Vanhoorelbeke
In vivo von Willebrand factor size heterogeneity in spite of the clinical deficiency of ADAMTS-13.
Journal of thrombosis and haemostasis : JTH 2011;9(12):2506-8.
2011: Karen De Ceunynck; Simon F De Meyer; Hans Deckmyn; Hendrik B Feys; Johan Hofkens; Susana Rocha; Hiroshi Uji-I; Karen Vanhoorelbeke
Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis.
The Journal of biological chemistry 2011;286(42):36361-7.
2011: Katleen Broos; Simon F De Meyer; Hendrik B Feys; Karen Vanhoorelbeke; Hans Deckmyn
Platelets at work in primary hemostasis.
Blood reviews 2011;25(4):155-67.
2010: B De Maeyer; S F De Meyer; H B Feys; Inge Pareyn; N Vandeputte; Hans Deckmyn; Karen Vanhoorelbeke
The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of platelet-decorated VWF strings in vivo.
Journal of thrombosis and haemostasis : JTH 2010;8(10):2305-12.
2010: Simon F De Meyer; Tobias Schwarz; Hans Deckmyn; Cécile V Denis; Bernhard Nieswandt; Guido Stoll; Karen Vanhoorelbeke; Christoph Kleinschnitz
Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(10):1949-51.
2010: Hendrik B Feys; Jan Roodt; Nele Vandeputte; Inge Pareyn; Seb Lamprecht; Walter J van Rensburg; Patricia J Anderson; Ulrich Budde; Vernon Louw; Philip N Badenhorst; Hans Deckmyn; Karen Vanhoorelbeke
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).
Blood 2010;116(12):2005-10.
2010: Hendrik Feys; N Vandeputte; Roberta Palla; Flora Peyvandi; Kathelijne Peerlinck; Hans Deckmyn; H Roger Lijnen; Karen Vanhoorelbeke
Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
Journal of thrombosis and haemostasis : JTH 2010;8(9):2053-62.
2009: Isabelle I Salles; Tim Thijs; Christine Brunaud; Simon F De Meyer; Johan Thys; Karen Vanhoorelbeke; Hans Deckmyn
Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34(+) cells are functionally active in an ex vivo flow model of thrombosis.
Blood 2009;114(24):5044-51.
2009: Hendrik Feys; Patricia Anderson; Karen Vanhoorelbeke; Elaine M Majerus; J Evan Sadler
Multi-step binding of ADAMTS-13 to von Willebrand factor.
Journal of thrombosis and haemostasis : JTH 2009;7(12):2088-95.
2009: Hendrik B Feys; Inge Pareyn; Renee Vancraenenbroeck; Marc De Maeyer; Hans Deckmyn; Chris Van Geet; Karen Vanhoorelbeke
Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura.
Blood 2009;114(21):4749-52.
2009: Karen Vanhoorelbeke; Simon F De Meyer; Inge Pareyn; Chantal Melchior; Sebastien Plançon; Christiane Margue; Olivier Pradier; Pierre Fondu; NELLY KIEFFER; Timothy A Springer; Hans Deckmyn
The novel S527F mutation in the integrin beta3 chain induces a high affinity alphaIIbbeta3 receptor by hindering adoption of the bent conformation.
The Journal of biological chemistry 2009;284(22):14914-20.
2009: Karen Vanhoorelbeke; Hendrik B Feys; Simon F De Meyer
ADAMTS13's tail tale.
Blood 2009;113(21):5039-40.
2009: Simon F De Meyer; Hans Deckmyn; Karen Vanhoorelbeke
von Willebrand factor to the rescue.
Blood 2009;113(21):5049-57.
2009: Christoph Kleinschnitz; Simon F De Meyer; Tobias Schwarz; Madeleine Austinat; Karen Vanhoorelbeke; Bernhard Nieswandt; Hans Deckmyn; Guido Stoll
Deficiency of von Willebrand factor protects mice from ischemic stroke.
Blood 2009;113(15):3600-3.
2009: Simon F De Meyer; Bauke De Maeyer; Hans Deckmyn; Karen Vanhoorelbeke
Von Willebrand factor: drug and drug target.
Cardiovascular & hematological disorders drug targets 2009;9(1):9-20.
2009: Hendrik B Feys; Hans Deckmyn; Karen Vanhoorelbeke
ADAMTS13 in health and disease.
Acta haematologica 2009;121(2-3):183-5.
2008: Armando Tripodi; Flora Peyvandi; Veena Chantarangkul; R Palla; A Afrasiabi; Maria Teresa Canciani; D W Chung; S Ferrari; Y Fujimura; M Karimi; K Kokame; J A Kremer Hovinga; B Lämmle; S F de Meyer; B Plaimauer; Karen Vanhoorelbeke; K Varadi; Pier M Mannucci
Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13).
Journal of thrombosis and haemostasis : JTH 2008;6(9):1534-41.
2008: Simon F De Meyer; Nele Vandeputte; Inge Pareyn; Inge Petrus; Peter J Lenting; Marinee K L Chuah; Thierry VandenDriessche; Hans Deckmyn; Karen Vanhoorelbeke
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(9):1621-6.
2008: Simon F De Meyer; Karen Vanhoorelbeke; Katleen Broos; Isabelle I Salles; Hans Deckmyn
Antiplatelet drugs.
British journal of haematology 2008;142(4):515-28.
2008: Isabelle I Salles; Hendrik Feys; Brecht F Iserbyt; Simon F De Meyer; Karen Vanhoorelbeke; Hans Deckmyn
Inherited traits affecting platelet function.
Blood reviews 2008;22(3):155-72.
2008: Flora Peyvandi; Silvia Lavoretano; Roberta Palla; Hendrik Feys; Karen Vanhoorelbeke; Tullia Battaglioli; Carla Valsecchi; Maria Teresa Canciani; Fabrizio Fabris; Samo Zver; Marienn Réti; Danijela Mikovic; zahrai zahra; Gaetano Giuffrida; Luca Laurenti; Pier Mannuccio Mannucci
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Haematologica 2008;93(2):232-9.
2007: Simon F De Meyer; Stephanie Staelens; Philip N Badenhorst; Henry Pieters; Seb Lamprecht; Jan Roodt; Stefan Janssens; Muriel Meiring; Karen Vanhoorelbeke; André Bruwer; Stephen Brown; Hans Deckmyn
Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor--collagen interaction in baboons.
Thrombosis and haemostasis 2007;98(6):1343-9.
2007: Kenneth Martin; Delphine Borgel; Nicolas Lerolle; Hendrik Feys; Ludovic Trinquart; Karen Vanhoorelbeke; Hans Deckmyn; Paulette Legendre; Jean-Luc Diehl; Dominique Baruch
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure.
Critical care medicine 2007;35(10):2375-82.
2007: Patricia Anderson; David Gailani; Hendrik Feys; Weiqiang Gao; Elaine M Majerus; Karen Vanhoorelbeke; J Evan Sadler
Factor XI/ADAMTS13 complexes are quantitatively insignificant in human plasma.
Haematologica 2007;92(10):1419-22.
2007: Wim Noppe; Fatima M Plieva; Karen Vanhoorelbeke; Hans Deckmyn; Mürvet Tuncel; Ali Tuncel; Igor Yu Galaev; Bo Mattiasson
Macroporous monolithic gels, cryogels, with immobilized phages from phage-display library as a new platform for fast development of affinity adsorbent capable of target capture from crude feeds.
Journal of biotechnology 2007;131(3):293-9.
2007: Hendrik Feys; Maria Teresa Canciani; Flora Peyvandi; Hans Deckmyn; Karen Vanhoorelbeke; Pier M Mannucci
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.
British journal of haematology 2007;138(4):534-40.
2007: Tímea Szántó; Agota Schlammadinger; Isabelle Salles; Inge Pareyn; Stephan Vauterin; Jolán Hársfalvi; Anne-Marie Vanden Bulcke; Hans Deckmyn; Karen Vanhoorelbeke
Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization.
Thrombosis and haemostasis 2007;98(1):251-4.
2007: Tímea Szántó; Agota Schlammadinger; Stephanie Staelens; Simon F De Meyer; Kathleen Freson; Inge Pareyn; Stephan Vauterin; Jolán Hársfalvi; Hans Deckmyn; Karen Vanhoorelbeke
The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha.
Thrombosis and haemostasis 2007;98(1):178-85.
2007: Peter J Lenting; Philip G de Groot; Simon F De Meyer; Karen Vanhoorelbeke; Cynthia Pruss; David Lillicrap; Isabelle Marx; Cécile V Denis
Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF.
Blood 2007;109(5):2267-8.
2007: Gerlinde Van de Walle; Anne Schoolmeester; Brecht F Iserbyt; Judith M E M Cosemans; Johan W M Heemskerk; Marc F Hoylaerts; Alan Nurden; Karen Vanhoorelbeke; Hans Deckmyn
Activation of alphaIIbbeta3 is a sufficient but also an imperative prerequisite for activation of alpha2beta1 on platelets.
Blood 2007;109(2):595-602.
2007: Karen Vanhoorelbeke; Hans Ulrichts; Gerlinde Van de Walle; alexandre fontayne; Hans Deckmyn
Inhibition of platelet glycoprotein Ib and its antithrombotic potential.
Current pharmaceutical design 2007;13(26):2684-97.
2007: Simon F De Meyer; Inge Pareyn; Jan Baert; Hans Deckmyn; Karen Vanhoorelbeke
False positive results in chimeraplasty for von Willebrand Disease.
Thrombosis research 2007;119(1):93-104.
2006: alexandre fontayne; Karen Vanhoorelbeke; Inge Pareyn; Isabel Van Rompaey; Muriel Meiring; Seb Lamprecht; Jan Roodt; Johan Desmet; Hans Deckmyn
Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4.
Thrombosis and haemostasis 2006;96(5):671-84.
2006: Simon F De Meyer; Karen Vanhoorelbeke; Hans Ulrichts; Stephanie Staelens; Hendrik Feys; I Salles; alexandre fontayne; Hans Deckmyn
Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.
Cardiovascular & hematological disorders drug targets 2006;6(3):191-207.
2006: Simon F De Meyer; Karen Vanhoorelbeke; Marinee K L Chuah; Inge Pareyn; Veerle Gillijns; Robert P Hebbel; Désiré Collen; Hans Deckmyn; Thierry VandenDriessche
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.
Blood 2006;107(12):4728-36.
2006: Claudine Caron; Lysiane Hilbert; Karen Vanhoorelbeke; Hans Deckmyn; Jenny Goudemand; Claudine Mazurier
Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
British journal of haematology 2006;133(6):655-63.
2006: Hendrik Feys; Fang Liu; Ning-zheng Dong; Inge Pareyn; Stephan Vauterin; N Vandeputte; Wim Noppe; C Ruan; Hans Deckmyn; Karen Vanhoorelbeke
ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.
Journal of thrombosis and haemostasis : JTH 2006;4(5):955-62.
2006: Agota Schlammadinger; Karen Vanhoorelbeke; Pal Laszlo; Zsuzsanna Bereczky; László Muszbek; Hans Deckmyn; Zoltán Boda
von Willebrand factor antigen latex immunoassays are affected to a different extent by rheumatoid factor.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(2):242-3.
2006: Fang Liu; Hendrik Feys; Ning-zheng Dong; Xia Bai; Karen Vanhoorelbeke; Hans Deckmyn; Chang-Geng Ruan
[Determination of the ADAMTS13 antigen and its activity in TTP patients and carriers].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2006;27(3):154-7.
2006: Stephanie Staelens; Johan Desmet; Thu-Hoa Ngo; Stephan Vauterin; Inge Pareyn; Philippe Barbeaux; Isabel Van Rompaey; Jean Marie Stassen; Hans Deckmyn; Karen Vanhoorelbeke
Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Molecular immunology 2006;43(8):1243-57.
2006: Hans Ulrichts; Miklós Udvardy; Peter J Lenting; Inge Pareyn; Nele Vandeputte; Karen Vanhoorelbeke; Hans Deckmyn
Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V.
The Journal of biological chemistry 2006;281(8):4699-707.
2006: Stephanie Staelens; Michael A Hadders; Stephan Vauterin; Céline Platteau; Marc De Maeyer; Karen Vanhoorelbeke; Eric G Huizinga; Hans Deckmyn
Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain.
The Journal of biological chemistry 2006;281(4):2225-31.
2006: Wim Noppe; Fatima M Plieva; Igor Yu Galaev; Karen Vanhoorelbeke; Bo Mattiasson; Hans Deckmyn
Immobilised peptide displaying phages as affinity ligands. Purification of lactoferrin from defatted milk.
Journal of chromatography. A 2006;1101(1-2):79-85.
2005: Gerlinde Van de Walle; Karen Vanhoorelbeke; Zsuzsa Majer; Eszter Illyés; Johan Baert; Inge Pareyn; Hans Deckmyn
Two functional active conformations of the integrin {alpha}2{beta}1, depending on activation condition and cell type.
The Journal of biological chemistry 2005;280(44):36873-82.
2005: Hai Po Helena Liang; Marie-Christine Morel-Kopp; Jeannine M Clemetson; Kenneth J Clemetson; riitta marjut kekomaki; Hartmut Kroll; Katerina Michaelides; Edward G D Tuddenham; Karen Vanhoorelbeke; Christopher M Ward
A common ancestral glycoprotein (GP) 9 1828A>G (Asn45Ser) gene mutation occurring in European families from Australia and Northern Europe with Bernard-Soulier Syndrome (BSS).
Thrombosis and haemostasis 2005;94(3):599-605.
2005: Hans Ulrichts; Karen Vanhoorelbeke; Jean-Pierre Girma; Peter J Lenting; Stephan Vauterin; Hans Deckmyn
The von Willebrand factor self-association is modulated by a multiple domain interaction.
Journal of thrombosis and haemostasis : JTH 2005;3(3):552-61.
2005: Hans Deckmyn; Nancy Cauwenberghs; Dongmei Wu; Hilde Depraetere; Karen Vanhoorelbeke
Development of antibodies that interfere with the collagen-VWF-GPIb axis as new antithrombotics.
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 2005;67(1):55-65.
2005: Karen Vanhoorelbeke; Inge Pareyn; Agota Schlammadinger; Stephan Vauterin; Marc F Hoylaerts; Jef Arnout; Hans Deckmyn
Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA.
Thrombosis and haemostasis 2005;93(1):165-71.
2004: Mario Hellings; Yves Engelborghs; Hans Deckmyn; Karen Vanhoorelbeke; Marion E Schiphorst; Jan-Willem N Akkerman; Marc De Maeyer
Experimental indication for the existence of multiple Trp rotamers in von Willebrand Factor A3 domain.
Proteins 2004;57(3):596-601.
2004: Wim Noppe; Karen Vanhoorelbeke; Igor Yu Galaev; Bo Mattiasson; Hans Deckmyn
A probe for capture and Fe3+-induced conformational change of lactoferrin selected from phage displayed peptide libraries.
Journal of dairy science 2004;87(10):3247-55.
2004: Hans Ulrichts; Karen Vanhoorelbeke; Gerlinde Van de Walle; S Katsutani; Simon F De Meyer; Stephanie Staelens; Hans Deckmyn
New approaches for antithrombotic antiplatelet therapies.
Current medicinal chemistry 2004;11(17):2261-3.
2004: Christelle Lecut; Anne Schoolmeester; Marijke J E Kuijpers; Jos L V Broers; Marc A M J van Zandvoort; Karen Vanhoorelbeke; Hans Deckmyn; Martine Jandrot-Perrus; Johan W M Heemskerk
Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(9):1727-33.
2004: Anne Schoolmeester; Karen Vanhoorelbeke; Shinya Katsutani; Hilde Depraetere; Hendrik Feys; Johan M W Heemskerk; Marc F Hoylaerts; Hans Deckmyn
Monoclonal antibody IAC-1 is specific for activated alpha2beta1 and binds to amino acids 199 to 201 of the integrin alpha2 I-domain.
Blood 2004;104(2):390-6.
2004: Hans Deckmyn; Hans Ulrichts; Gerlinde Van de Walle; Karen Vanhoorelbeke
Platelet antigens and their function.
Vox sanguinis 2004;87 Suppl 2():105-11.
2004: Andrei Musaji; Karen Vanhoorelbeke; Hans Deckmyn; Jean-Paul Coutelier
New model of transient strain-dependent autoimmune thrombocytopenia in mice immunized with rat platelets.
Experimental hematology 2004;32(1):87-94.
2004: Karen Vanhoorelbeke; Hans Ulrichts; Roland A Romijn; Eric G Huizinga; Hans Deckmyn
The GPIbalpha-thrombin interaction: far from crystal clear.
Trends in molecular medicine 2004;10(1):33-9.
2003: Karen Vanhoorelbeke; Hilde Depraetere; Roland A Romijn; Eric G Huizinga; Marc De Maeyer; Hans Deckmyn
A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction.
The Journal of biological chemistry 2003;278(39):37815-21.
2003: Hans Ulrichts; Karen Vanhoorelbeke; Sandra Cauwenberghs; Stephan Vauterin; Hartmut Kroll; Sentot Santoso; Hans Deckmyn
von Willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(7):1302-7.
2003: Karen Vanhoorelbeke; Hans Ulrichts; Anne Schoolmeester; Hans Deckmyn
Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs.
Current drug targets. Cardiovascular & haematological disorders 2003;3(2):125-40.
2002: Dongmei Wu; Karen Vanhoorelbeke; Nancy Cauwenberghs; Muriel Meiring; Hilde Depraetere; Harry F Kotze; Hans Deckmyn
Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons.
Blood 2002;99(10):3623-8.
2002: Karen Vanhoorelbeke; Nancy Cauwenberghs; Griet Vandecasteele; Stephan Vauterin; Hans Deckmyn
A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
Seminars in thrombosis and hemostasis 2002;28(2):161-6.
2001: Nancy Cauwenberghs; Karen Vanhoorelbeke; Stephan Vauterin; D F Westra; Gabriel M Romo; Eric G Huizinga; Jose A Lopez; Michael C Berndt; Jolan Harsfalvi; Hans Deckmyn
Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha.
Blood 2001;98(3):652-60.
2001: Karen Vanhoorelbeke; Agota Schlammadinger; JP Delville; J Handsaeme; Griet Vandecasteele; Stephan Vauterin; O Pradier; W Wijns; Hans Deckmyn
Occurrence of the Asn45Ser mutation in the GPIX gene in a Belgian patient with Bernard Soulier syndrome.
Platelets 2001;12(2):114-20.
2000: Nancy Cauwenberghs; Karen Vanhoorelbeke; Stephan Vauterin; Hans Deckmyn
Structural determinants within platelet glycoprotein Ibalpha involved in its binding to von Willebrand factor.
Platelets 2000;11(7):373-8.
2000: Karen Vanhoorelbeke; RM van der Plas; Griet Vandecasteele; Stephan Vauterin; Eric G Huizinga; Jan J Sixma; Hans Deckmyn
Sequence alignment between vWF and peptides inhibiting the vWF-collagen interaction does not result in the identification of a collagen-binding site in vWF.
Thrombosis and haemostasis 2000;84(4):621-5.
2000: Karen Vanhoorelbeke; Nancy Cauwenberghs; Stephan Vauterin; Agota Schlammadinger; Claudine Mazurier; Hans Deckmyn
A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor.
Thrombosis and haemostasis 2000;83(1):107-13.
1998: H Deckmyn; Karen Vanhoorelbeke; K Peerlinck
Inhibitory and activating human antiplatelet antibodies.
Baillière's clinical haematology 1998;11(2):343-59.
1997: Hans Deckmyn; Karen Vanhoorelbeke; Nancy Cauwenberghs
A platelet-activating antiglycoprotein Ib monoclonal antibody.
Blood 1997;90(9):3807-8.